A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females With Rett Syndrome
Latest Information Update: 02 Jun 2025
At a glance
- Drugs TSHA 102 (Primary)
- Indications Rett syndrome
- Focus Adverse reactions
- Acronyms REVEAL; REVEAL Pediatric Study
- Sponsors Taysha Gene Therapies
Most Recent Events
- 28 May 2025 According to a Taysha Gene Therapies media release, company will host three oral presentations related to TSHA-102 at the upcoming 2025 IRSF Rett Syndrome Scientific Meeting taking place in Boston from June 9-11, 2025.
- 28 May 2025 Results presented in the Taysha Gene Therapies media release.
- 28 May 2025 According to a Taysha Gene Therapies media release, companyannounced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).